Recently, using a MUC1.Tg lung cancer mouse model, it was demonstrated that pre-administration of cyclophosphamide (CPA) with BLP25 increases the levels of the immune stimulating T-helper 1 (Th1) response [IL-2 and interferon gamma (IFN-γ)], as well as other inflammatory chemokines such as IP-10, MIG, KC, MCP-1, and MIP-1α (22), may enhance immunotherapy by boosting both cellular and humoral mediated antitumor immune responses for the vaccine by inhibiting regulatory T (Treg) cells (24–26). This evidence concerns the gene IFNG and lung cancer.